RYEQO (Gedeon Richter Australia Pty Ltd)
Product name
RYEQO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
174 (255 working days)
Active ingredients
estradiol, norethisterone acetate, relugolix
Registration type
EOI
Indication
Ryeqo is indicated in adult women of reproductive age for:
- treatment of moderate to severe symptoms of uterine fibroids,
- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (see section 5.1 PHARMACODYNAMIC PROPERTIES).